Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1)

What Was Tested

The paper reports a study of Glucagon and GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.

The insulinotropic hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1), regulate insulin secretion to nutrient intake and constitute the endocrine arm of the entero-insular axis.

Glucagon has been implicated in the pathophysiology of conditions characterised by abnormal glucose tolerance such as obesity and diabetes mellitus although its effect on the entero-insular axis is not fully understood.

Who Took Part

The age groups tagged for this paper are adults, men only.

How the Study Was Run

In design terms this was a randomized, single-blind and pilot study.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

In this single-blind Glucagon study one party knew the assignments and the other did not.

It is described as a pilot, a small early test of whether a larger Glucagon study would be practical.

What Was Measured

The subject headings attached to it are Acetaminophen, Analgesics, Non-Narcotic, Blood Glucose, Carbohydrates, Gastric Emptying, Gastric Inhibitory Polypeptide and Gastrointestinal Agents.

What This Means in Plain Language

The paper is a randomized, single-blind and pilot study of Glucagon and GIP (Gastric Inhibitory Polypeptide).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1999 (Diabetes/metabolism research and reviews), a journal based in England.

More context: the Glucagon compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.